Accurate Noninvasive Test of Steatorrhea in Infants

婴儿脂肪泻的准确无创检测

• 批准号: 6625970
• 负责人: MORTEZA JANGHORBANI
• 金额: $ 29.25万
• 依托单位: BIOCHEMANALYSIS CORPORATION
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-01 至 2005-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6625970
• 关键词: baby food; clinical research; cystic fibrosis; diagnosis design /evaluation; dietary lipid; dyes; feces analysis; gastrointestinal disorder diagnosis; human milk; human subject; infant human (0-1 year); lipid metabolism; malabsorption; noninvasive diagnosis; stable isotope; stable isotope diagnosis; steatorrhea; triglycerides

DESCRIPTION (provided by the applicant): The long-term objectives of this proposed project are to develop a "Test Kit" for quantitative assessment of steatorrhea in infants without the need for control of dietary fat intake and quantitative collections of stools for several days as is the case with the current "Gold Standard," viz, the 72-hour fecal fat method. Our proposed "Test Kit" is based on administering a feeding of infant formula containing a suitably labeled 13C-triglyceride (TG), a trace amount of the nonabsorbable marker dysprosium chloride (DyC1-3) and the visual marker Brilliant Blue followed by laboratory analysis of Dy and 13C-Excess in one or more sample(s) of stool containing the visual marker. The research conducted during Phase-I of this grant has led to the selection of 1,3-(13C-2) dipalmitoyl, 2-lauryl glycerol (P*LP*) as the most suitable TG* for applications in infants. During Phase II of the project, we propose to conduct clinical protocols with cystic fibrosis and healthy infants in order to: (1) define the parameters of the expected linear correlation between fecal excretion of P*LP* and fecal fat, (2) demonstrate the significance of this novel method in medical management of infants with steatorrhea, and (3) obtain research data necessary for the manufacture of a safe and noninvasive "Test Kit" for accurate assessment of steatorrhea in infants. The "Test Kit" has widespread applications in clinical management of infants with a wide range of disorders leading to steatorrhea.

描述（由申请人提供）：本项目的长期目标 建议的项目是开发一个“测试工具包”， 不需要控制膳食脂肪摄入量的婴儿脂肪摄入量， 定量收集粪便数天，如 目前的“黄金标准”，即72小时粪便脂肪法。我们提出的“测试 试剂盒”是基于施用含有以下成分的婴儿配方的喂养： 适当标记的13 C-甘油三酯（TG），微量的不可吸收的 标记物氯化镝（DyC 1 -3）和目视标记物亮蓝 随后对一个或多个样品中的Dy和13 C过量进行实验室分析 含有视觉标记的粪便。第一阶段的研究 该资助导致选择1，3-（13 C-2）二棕榈酰、2-月桂酰 甘油（P*LP*）作为最适合应用于婴儿的TG*。期间 第二阶段的项目，我们建议进行临床协议与囊性 纤维化和健康婴儿，以便：（1）定义纤维化的参数。 P*LP* 粪便排泄量与粪便脂肪之间的预期线性相关性，（2） 证明了这种新方法在医疗管理中的重要性， 婴儿与脂肪，（3）获得必要的研究数据， 制造安全和非侵入性的“检测试剂盒”，用于准确评估 婴儿的肥胖症。该试剂盒已广泛应用于临床 管理患有各种导致肥胖症的疾病的婴儿。